Laura Y Wang1, Benjamin R Roman1, Frank L Palmer1, R Michael Tuttle2, Ashok R Shaha1, Jatin P Shah1, Snehal G Patel1, Ian Ganly3. 1. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Medicine, Endocrine, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: ganlyi@mskcc.org.
Abstract
BACKGROUND: Over the last 15 years, there has been a change in clinical practice for the detection of recurrence in all patients with papillary thyroid cancer (PTC). In the past, recurrence was detected by clinical examination supplemented with fine-needle aspiration cytology; however, routine neck ultrasonography (US) and measurements of serum thyroglobulin were introduced for follow-up in 2000 and are now used widely for recurrence surveillance. The aim of this study was to describe the effectiveness of this changing trend in the use of routine surveillance ultrasonography for the detection of recurrence in low-risk PTC at a single institution. METHODS: Patients undergoing total thyroidectomy for PTC between January 2000 and December 2010 were identified from an institutional database. Of these, 752 (43.1%) were categorized as low risk by the risk stratification of the American Thyroid Association and included for analysis. The number of US examinations per patient per year of follow-up was then determined. The number of recurrences and deaths from disease was recorded similarly. RESULTS: The median age was 48 years (range, 16-83) and the median follow-up was 34 months (range, 1-148). Between 2003 and 2012, the number of US examinations per patient-year of follow-up increased by 5.3-fold. Over the same time period, 3 structural recurrences (clinically evident neck masses or nodes) were detected with no disease-related deaths. CONCLUSION: At our institution, the annual rate of neck US examination increased by 5.3-fold per low-risk PTC patients between 2003 and 2012. Despite this increase, only 3 structural recurrences were detected. The routine use of neck US for surveillance of low-risk PTC patients requires review.
BACKGROUND: Over the last 15 years, there has been a change in clinical practice for the detection of recurrence in all patients with papillary thyroid cancer (PTC). In the past, recurrence was detected by clinical examination supplemented with fine-needle aspiration cytology; however, routine neck ultrasonography (US) and measurements of serum thyroglobulin were introduced for follow-up in 2000 and are now used widely for recurrence surveillance. The aim of this study was to describe the effectiveness of this changing trend in the use of routine surveillance ultrasonography for the detection of recurrence in low-risk PTC at a single institution. METHODS:Patients undergoing total thyroidectomy for PTC between January 2000 and December 2010 were identified from an institutional database. Of these, 752 (43.1%) were categorized as low risk by the risk stratification of the American Thyroid Association and included for analysis. The number of US examinations per patient per year of follow-up was then determined. The number of recurrences and deaths from disease was recorded similarly. RESULTS: The median age was 48 years (range, 16-83) and the median follow-up was 34 months (range, 1-148). Between 2003 and 2012, the number of US examinations per patient-year of follow-up increased by 5.3-fold. Over the same time period, 3 structural recurrences (clinically evident neck masses or nodes) were detected with no disease-related deaths. CONCLUSION: At our institution, the annual rate of neck US examination increased by 5.3-fold per low-risk PTCpatients between 2003 and 2012. Despite this increase, only 3 structural recurrences were detected. The routine use of neck US for surveillance of low-risk PTCpatients requires review.
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Steven I Sherman; R Michael Tuttle Journal: Thyroid Date: 2006-02 Impact factor: 6.568
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Laura Y Wang; Frank L Palmer; Dorothy Thomas; Ashok R Shaha; Jatin P Shah; Snehal G Patel; R Michael Tuttle; Ian Ganly Journal: J Clin Endocrinol Metab Date: 2014-07-25 Impact factor: 5.958
Authors: F Pacini; E Molinaro; M G Castagna; L Agate; R Elisei; C Ceccarelli; F Lippi; D Taddei; L Grasso; A Pinchera Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: Joshua M Evron; David Reyes-Gastelum; Mousumi Banerjee; Laura D Scherer; Lauren P Wallner; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Brian J Zikmund-Fisher; Megan R Haymart Journal: J Clin Oncol Date: 2019-10-01 Impact factor: 50.717